Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team. Wohl DA, et al. Among authors: andersen j. HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143. HIV Clin Trials. 2009. PMID: 19632953 Free PMC article. Clinical Trial.
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA; A5030 Study Team. Wohl DA, et al. PLoS One. 2013 Nov 15;8(11):e78676. doi: 10.1371/journal.pone.0078676. eCollection 2013. PLoS One. 2013. PMID: 24260125 Free PMC article. Clinical Trial.
The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.
Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ; ACTG 379 Study Team. Wohl DA, et al. Among authors: andersen j. HIV Clin Trials. 2005 May-Jun;6(3):136-46. doi: 10.1310/4J65-4YX1-4ET6-E5KR. HIV Clin Trials. 2005. PMID: 16192248 Clinical Trial.
Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma.
Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andersen J, Manjiry R, Crumpacker C, Lurain NS, Erice A; CMV Working Group of the Complications of HIV Disease RAC, AIDS Clinical Trials Group. Caliendo AM, et al. Among authors: andersen j. J Clin Microbiol. 2001 Apr;39(4):1334-8. doi: 10.1128/JCM.39.4.1334-1338.2001. J Clin Microbiol. 2001. PMID: 11283052 Free PMC article.
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.
MacGregor RR, Hafner R, Wu JW, Murphy RL, Perlman DC, Bermudez LE, Inderlied CB, Picker LJ, Wallis RS, Andersen JW, Mahon LF, Koletar SL, Peterson DM; ACTG Protocol 341 Team. MacGregor RR, et al. Among authors: andersen jw. AIDS Res Hum Retroviruses. 2005 Aug;21(8):689-95. doi: 10.1089/aid.2005.21.689. AIDS Res Hum Retroviruses. 2005. PMID: 16131307
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. Swindells S, et al. Among authors: andersen j. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. N Engl J Med. 2019. PMID: 30865794 Free PMC article. Clinical Trial.
4,226 results